| Inclusion criteria (patients were eligible if all of the following applied) |
|
| (1) Classified MS diagnosis |
|
| (2) Written informed consent has been obtained |
|
| (3) Patients are willing and able to complete the micturition diary correctly |
|
| (4) Complaints of OAB |
|
| (a) Urgency/Frequency (micturition frequency > 8/day) |
|
| (b) Urge incontinence (involuntary loss of urine after a sensation of urge) |
|
| Exclusion criteria (patients would be excluded from participation if any of the following apply) |
|
| (1) Significant postvoid residual volume (PVR >200 mL) |
|
| (2) Evidence of a urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs |
|
| (3) Uncontrolled narrow angle glaucoma, urinary or gastric retention, or any other medical condition which in the opinion of the investigator makes the use of anticholinergics contra-indicated |
|
| (4) Non-drug treatment including electrostimulation therapy or start of a bladder training program during the 12 weeks prior to or during the study |
|
| (5) Use of drugs intended to treat urinary incontinence |
|
| (6) Known or suspected hypersensitivity to other anticholinergics or lactose |
|
| (7) Any clinical significant condition, which in the opinion of the investigator makes the patient unsuitable for the trial |
|
| (8) Pregnancy or the wish to become pregnant during the study |
|
